Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy

• Published in: Human gene therapy Vol. 28; no. 5; p. 428
• Main Authors: Ito, Mikako, Ehara, Yuka, Li, Jin, Inada, Kosuke, Ohno, Kinji
• Format: Journal Article
• Language: English
• Published: United States 01.05.2017
• Subjects: Animals; Biglycan - administration & dosage; Biglycan - genetics; Disease Models, Animal; Dystrophin-Associated Proteins - genetics; Extracellular Matrix Proteins - administration & dosage; Extracellular Matrix Proteins - genetics; Gene Expression Regulation; Humans; Mice; Mice, Inbred mdx; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Muscular Dystrophy, Animal - genetics; Muscular Dystrophy, Animal - pathology; Muscular Dystrophy, Animal - therapy; Muscular Dystrophy, Duchenne - genetics; Muscular Dystrophy, Duchenne - pathology; Muscular Dystrophy, Duchenne - therapy; Utrophin - genetics; extracellular matrix protein; protein-anchoring therapy; adeno-associated virus type 8; dystrophin; biglycan; Duchenne muscular dystrophy
• ISSN: 1557-7422
• DOI: 10.1089/hum.2015.088

Duchenne muscular dystrophy (DMD) is a devastating muscle disease caused by loss-of-function mutations in DMD encoding dystrophin. No rational therapy is currently available. Utrophin is a paralog of dystrophin and is highly expressed at the neuromuscular junction. In mdx mice, utrophin is naturally upregulated throughout the muscle fibers, which mitigates muscular dystrophy. Protein-anchoring therapy was previously reported, in which a recombinant extracellular matrix (ECM) protein is delivered to and anchored to a specific target using its proprietary binding domains. Being prompted by a report that intramuscular and intraperitoneal injection of an ECM protein, biglycan, upregulates expression of utrophin and ameliorates muscle pathology in mdx mice, protein-anchoring therapy was applied to mdx mice. Recombinant adeno-associated virus serotype 8 (rAAV8) carrying hBGN encoding human biglycan was intravenously injected into 5-week-old mdx mice. The rAAV8-hBGN treatment improved motor deficits and decreased plasma creatine kinase activities. In muscle sections of treated mice, the number of central myonuclei and the distribution of myofiber sizes were improved. The treated mice increased gene expressions of utrophin and β1-syntrophin, as well as protein expressions of biglycan, utrophin, γ-sarcoglycan, dystrobrevin, and α1-syntrophin. The expression of hBGN in the skeletal muscle of the treated mice was 1.34-fold higher than that of the native mouse Bgn (mBgn). The low transduction efficiency and improved motor functions suggest that biglycan expressed in a small number of muscle fibers was likely to have been secreted and anchored to the cell surface throughout the whole muscular fibers. It is proposed that the protein-anchoring strategy can be applied not only to deficiency of an ECM protein as previously reported, but also to augmentation of a naturally induced ECM protein.